Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 8 |
| 2018 | 6 |
| 2019 | 5 |
| 2020 | 13 |
| 2021 | 13 |
| 2022 | 26 |
| 2023 | 26 |
| 2024 | 40 |
| 2025 | 52 |
| 2026 | 15 |
Search Results
198 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Ulcerative colitis.
Lancet. 2023 Aug 12;402(10401):571-584. doi: 10.1016/S0140-6736(23)00966-2.
Lancet. 2023.
PMID: 37573077
Review.
Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent. In 2023, the prevalence of ulcerative colitis was estimated to be 5 million cases around the world, and the incidence is increasing worldwide. ...Maintenance t …
Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent. In 2023, the preval …
Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice.
World J Gastroenterol. 2025 Aug 7;31(29):107745. doi: 10.3748/wjg.v31.i29.107745.
World J Gastroenterol. 2025.
PMID: 40809925
Free PMC article.
Review.
Over the past decade, the therapeutic armamentarium for inflammatory bowel disease (IBD) has substantially expanded with the incorporation of multiple classes of advanced therapies. Currently, in addition to tumor necrosis factor-alpha inhibitors, the therape …
Over the past decade, the therapeutic armamentarium for inflammatory bowel disease (IBD) has substantially expanded wit …
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
Cytokine Growth Factor Rev. 2023 Jun-Aug;71-72:1-12. doi: 10.1016/j.cytogfr.2023.07.001. Epub 2023 Jul 13.
Cytokine Growth Factor Rev. 2023.
PMID: 37455149
Review.
Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has multiple effective treatment options available and new therapeutic strategies are being actively explored to further increase the treatment options for pat …
Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has multiple effect …
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.
Drugs. 2024 Oct;84(10):1179-1197. doi: 10.1007/s40265-024-02094-5. Epub 2024 Sep 26.
Drugs. 2024.
PMID: 39322927
Free PMC article.
Review.
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) are chronic immune-mediated diseases which primarily target the intestines. ...We also present recent data on emerging S1P modulators. Finally, …
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) are chronic immune …
Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Medicina (Kaunas). 2024 Jan 31;60(2):250. doi: 10.3390/medicina60020250.
Medicina (Kaunas). 2024.
PMID: 38399538
Free PMC article.
Review.
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, necessitates long-term medical therapy to manage symptoms and prevent complications. ...
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, necessitates …
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
N Engl J Med. 2021 Sep 30;385(14):1302-1315. doi: 10.1056/NEJMra1907607.
N Engl J Med. 2021.
PMID: 34587387
Review.
No abstract available.
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Gastroenterology. 2024 Dec;167(7):1460-1482. doi: 10.1053/j.gastro.2024.07.046. Epub 2024 Oct 18.
Gastroenterology. 2024.
PMID: 39425738
Free PMC article.
METHODS: We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderate-to-severe UC, comparing different advanced therapies (tumor necrosis factor antagonists, vedolizumab, sphingosine-1-phos …
METHODS: We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with modera …
Etrasimod for the treatment of ulcerative colitis.
Immunotherapy. 2023 Apr;15(5):311-321. doi: 10.2217/imt-2022-0255. Epub 2023 Feb 15.
Immunotherapy. 2023.
PMID: 36789612
Review.
Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. ...Etrasimod is a new and promising drug for ulcerative colit …
Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflamma …
Treatment Strategies in Inflammatory Bowel Diseases.
Dtsch Arztebl Int. 2023 Nov 10;120(45):768-778. doi: 10.3238/arztebl.m2023.0142.
Dtsch Arztebl Int. 2023.
PMID: 37408514
Free PMC article.
Review.
BACKGROUND: The prevalence of inflammatory bowel disease (IBD) is rising globally. In Germany, these conditions affect 0.7% of the population, or approximately 600 000 patients. ...RESULTS: An improved understanding of the immunological mechanisms of disea …
BACKGROUND: The prevalence of inflammatory bowel disease (IBD) is rising globally. In Germany, these conditions affect …
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
N Engl J Med. 2021.
PMID: 34587385
Clinical Trial.
BACKGROUND: Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease. ...
BACKGROUND: Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of i …
Cite